Page 1

THE PEER-REVIEWED FORUM FOR REAL-WORLD EVIDENCE IN BENEFIT DESIGN ™ OCTOBER 2014

VOLUME 7, NUMBER 7

FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS

EDITORIAL

Personalized Medicine: Are We There Yet? David B. Nash, MD, MBA PERSPECTIVE

Rewarding Innovation in Drug Development Emily Saadi and Greg White, MPP CLINICAL ™

Evaluation of Dabigatran for Appropriateness of Use and Bleeding Events in a Community Hospital Setting Anastasia L. Armbruster, PharmD, BCPS; Katie S. Buehler, PharmD, BCPS; Sun H. Min, PharmD; Margaret Riley, PharmD; Michael W. Daly, PharmD, MSCI, BCPS Stakeholder Perspective: Accurate Prescribing Key to Safe Use of Anticoagulants in Patients with Nonvalvular Atrial Fibrillation By Raymond L. Singer, MD, MMM, CPE

Patient Preferences and Treatment Adherence Among Women Diagnosed with Metastatic Breast Cancer Marco daCosta DiBonaventura, PhD; Ronda Copher, PhD; Enrique Basurto, MSc; Claudio Faria, PharmD, MPH; Rose Lorenzo, BA Stakeholder Perspective: Predicting Behavior: It’s a Matter of Preference By Albert Tzeel, MD, MHSA, FACPE

AMCP Nexus 2014 Highlights

© 2014 Engage Healthcare Communications, LLC

www.AHDBonline.com

Profile for Dalia Buffery

AHDB October 2014, Vol 7, No 7  

American Health & Drug Benefits October 2014, Vol 7, No 7

AHDB October 2014, Vol 7, No 7  

American Health & Drug Benefits October 2014, Vol 7, No 7

Advertisement